Key result
Pravastatin 40 mg daily reduced all-cause mortality compared to placebo (7.9% vs 9.8%; RRR 20%, 95% CI 12-27%, P<0.0001) over 5 to 6 years in patients with and without coronary heart disease.
Why the study?
Does pravastatin 40 mg daily reduce all-cause and coronary mortality in patients with and without coronary heart disease?
Population
19,768 patients, comprising 13,173 patients with coronary heart disease and 6,595 men with elevated…
Comparison
Pravastatin 40 mg daily vs Placebo
Design
Meta-analysis
Follow-up
average of 5 to 6 years
Authors
Loading...
Supports statin use to reduce mortality in primary and secondary prevention; reinforces benefits across broad cholesterol levels in randomized evidence.
Meta-Analysis (n=19,768)
Yes
Does pravastatin 40 mg daily reduce all-cause and coronary mortality in patients with and without coronary heart disease?
Effect estimate: RRR 20% (95% CI 12-27)
Absolute Event Rate: 7.9% vs 9.8%
p-value: p=<0.0001
Pravastatin 40 mg daily over 5-6 years significantly reduces all-cause and coronary mortality across a broad range of cholesterol levels in patients with and without prior coronary heart disease.
John Simes (2002) conducted a meta-analysis in Coronary heart disease or elevated cholesterol (n=19,768). Pravastatin vs. Placebo was evaluated on all-cause mortality (RRR 20%, 95% CI 12-27, p=<0.0001). Pravastatin 40 mg daily reduced all-cause mortality compared to placebo (7.9% vs 9.8%; RRR 20%, 95% CI 12-27%, P<0.0001) over 5 to 6 years in patients with and without coronary heart disease.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: